Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
SAN DIEGO, Feb. 27, 2017 -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its fourth quarter and full year 2016 financial results after the market closes on Tuesday, March 7, 2017 followed by a conference call at 4:30 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review financial results and discuss other business matters.
The conference call dial-in numbers are (855) 765-5682 for domestic callers and (919) 825-3204 for international callers. The conference ID number for the call is 78309371. Participants may access the live webcast via a link on the Vital Therapies website in the ‘Investor Relations’ section under ‘Events’ at: http://ir.vitaltherapies.com/. The webcast will be archived on the Company's website shortly after completion of the call.
For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 7:30 p.m. ET on March 7, 2017 to March 14, 2017. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 78309371.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company's ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
Contact: Vital Therapies, Inc. Al Kildani Vice President, Investor Relations and Business Development 858-673-6840 [email protected]
